Eight million people living with HIV. Just over 6 million on treatment. Behind these big numbers lurk a universe of fascinating epidemiological dynamics. In this special briefing, Spotlight editor Marcus Low unpacks what we know about the state of HIV in South Africa.
Massive gains have been made in reducing new HIV infections and deaths in children. Yet, many of the statistics for children still look worse than those for adults. Elri Voigt asked experts why this is the case and what factors prevent children living with HIV from starting and staying on the treatment that can keep them healthy.
US funding for clinical research in South Africa is incrementally being cancelled. This is happening through at least two processes – the first is by banning certain kinds of foreign grants called sub-awards (which is affecting everyone globally). The second is by failing to issue routine renewals of grants for clinical studies in South Africa. Spotlight and GroundUp break down the current situation.
It is widely acknowledged among health and demographic experts that relying solely on what is written on death certificates does not paint an accurate picture of what people in South Africa are actually dying of. Now, an SAMRC study has provided evidence that the undercounting of deaths due to HIV might be even greater than previously thought. Chris Bateman reports.
We’re watching the largest HIV treatment programme in the world unravelling in real time. We don’t need perfection, but we do need a combination of urgency, action, and strategy to save it, argues Professor Francois Venter.
In late-January, the US suspended billions of dollars worth of international aid, including for HIV-related programmes in South Africa. The South African government could have responded by triggering an emergency funding mechanism but has failed to do so yet. In the meantime, activists, health researchers and even technical advisors to government are growing increasingly frustrated with the government’s lack of transparency on this issue.
Top local researchers estimate that the cancellation of funding from the US President’s Emergency Plan for AIDS Relief could lead to a significant increase in HIV infections and deaths in South Africa. Jesse Copelyn reports.
There is no shortage of myths about the cancellation of US foreign assistance. This includes the widely held misconception that PEPFAR is exempt from US aid cuts and the belief that grant terminations are just taking place in South Africa. Many of these falsehoods have been reinforced by US and South African officials. Spotlight and GroundUp dissect some of the most popular misconceptions.
The number of people living with HIV in South Africa has for the first time reached the eight million mark. Of these, around 6.2 million are on treatment, according to new estimates. Marcus Low reports.
After the US slashed global aid, the South African government stated that only 17% of its HIV spending relied on US funding. But some experts argue that US health initiatives had more bang for buck than the government’s programmes. Jesse Copelyn looks past the 17% figure, and considers how the health system is being affected by the loss of US money.
A groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in funding from the United States government. As a result, several promising vaccine candidates might not be tested in clinical trials. Catherine Tomlinson reports.
Amid major disruptions caused by aid cuts from the United States government, the health department aims to enrol a record number – an additional 1.1 million – of people living with HIV on life-saving antiretroviral medicine this year. Experts tell Spotlight it can’t be business as usual if this ambitious programme is to have a chance of succeeding. Ufrieda Ho reports.
